LON:FARN Faron Pharmaceuticals Oy Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. GBX 215 -2.50 (-1.15%) (As of 06/29/2022 12:00 AM ET) Add Compare Share Today's Range 206▼ 21550-Day Range 200▼ 24052-Week Range 200▼ 495Volume992 shsAverage Volume19,901 shsMarket Capitalization£114.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsInsider TradesHeadlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FARN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter. Email Address FARN Stock Forecast (MarketRank)Overall MarketRank™1.00 out of 5 starsAnalyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Faron Pharmaceuticals Oy. Previous Next 5.0 Community Rank Outperform VotesFaron Pharmaceuticals Oy has received 317 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFaron Pharmaceuticals Oy has received 92 “underperform” votes. (Add your “underperform” vote.)Community SentimentFaron Pharmaceuticals Oy has received 77.51% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Faron Pharmaceuticals Oy and other stocks. Vote “Outperform” if you believe FARN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FARN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFaron Pharmaceuticals Oy does not currently pay a dividend.Dividend GrowthFaron Pharmaceuticals Oy does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Faron Pharmaceuticals Oy insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Faron Pharmaceuticals Oy is -5.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Faron Pharmaceuticals Oy is -5.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFaron Pharmaceuticals Oy has a P/B Ratio of 39.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Faron Pharmaceuticals Oy (LON:FARN)Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.Read More FARN Stock News HeadlinesJune 28, 2022 | proactiveinvestors.comFaron Pharma raises €5mln; brings in leading charity as an investorJune 8, 2022 | proactiveinvestors.comFaron Pharmaceuticals doses first patient in bexmarilimab combination studyMay 30, 2022 | proactiveinvestors.comFaron Pharma to showcase the potential of cancer drug at ASCO conferenceMay 16, 2022 | proactiveinvestors.comFaron Pharmaceuticals Oy excited by green light for trials of promising anti-cancer treatmentMay 16, 2022 | finance.yahoo.comFaron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic MalignanciesApril 21, 2022 | finance.yahoo.comFaron Presents Results from Melanoma Cohort of MATINS Trial at 18th Congress of the European Association of Dermato-Oncology (EADO)April 5, 2022 | proactiveinvestors.comFaron Pharmaceuticals halts COVID-19 trial as hospital cases dropMarch 14, 2022 | proactiveinvestors.comFaron Pharma identifies possible reason for interferon-beta and steroid clashMarch 10, 2022 | proactiveinvestors.com.auFaron Pharmaceuticals will present findings at American Association for Cancer Research annual meetingFebruary 28, 2022 | proactiveinvestors.comFaron Pharmaceuticals agrees funding deal worth up to €30mlnFebruary 28, 2022 | finance.yahoo.comFaron Obtains Debt Funding from IPF PartnersFebruary 14, 2022 | finance.yahoo.comFaron Announces R&D DayFebruary 3, 2022 | proactiveinvestors.comFaron Pharmaceuticals says Traumakine study shows induction of CD73 molecule prevents death after emergency open aortic surgerySee More Headlines Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:FARN CUSIPN/A CIKN/A Webwww.faron.com Phone+358-2-4695151FaxN/AEmployees37Year FoundedN/ACompany Calendar Today6/29/2022Next Earnings (Estimated)8/25/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio121.51 Current Ratio1.68 Quick Ratio1.15 Sales & Book Value Annual Sales£6.14 million Price / Sales18.65 Cash FlowGBX 13.46 per share Price / Cash Flow15.97 Book ValueGBX 5.50 per share Price / Book39.09Miscellaneous Outstanding Shares53,232,000Free FloatN/AMarket Cap£114.45 million OptionableNot Optionable BetaN/A Faron Pharmaceuticals Oy Frequently Asked Questions How has Faron Pharmaceuticals Oy's stock price performed in 2022? Faron Pharmaceuticals Oy's stock was trading at GBX 270 on January 1st, 2022. Since then, FARN stock has decreased by 20.4% and is now trading at GBX 215. View the best growth stocks for 2022 here. When is Faron Pharmaceuticals Oy's next earnings date? Faron Pharmaceuticals Oy is scheduled to release its next quarterly earnings announcement on Thursday, August 25th 2022. View our earnings forecast for Faron Pharmaceuticals Oy. Who are Faron Pharmaceuticals Oy's key executives? Faron Pharmaceuticals Oy's management team includes the following people: Dr. Juho Markku Jalkanen M.D., MSc, Ph.D., Chief Operating Officer (Age 44, Pay $473.34k)Dr. Markku Tapani Jalkanen Ph.D., Founder, CEO & Exec. Director (Age 68)Mr. Toni Hänninen, Chief Financial OfficerEric Van Zanten, Head of CommunicationsDr. Juhana Heinonen, Chief Commercial OfficerDr. Marie-Louise Fjallskog M.D., Ph.D., Chief Medical Officer (Age 58)Dr. Ilse Piippo, Regulatory Consultant (Age 73) Who are some of Faron Pharmaceuticals Oy's key competitors? Some companies that are related to Faron Pharmaceuticals Oy include Oxford Biomedica (OXB), Pfenex (PFNX), Dyne Therapeutics (DYN), ProMetic Life Sciences (PLI), Horizon Discovery Group plc (HZD.L) (HZD), Theratechnologies (TH), Precigen (PGEN), VIVO Cannabis (ABCN), Emblem (EMC), Inventiva (IVA), Verona Pharma plc (VRP.L) (VRP), VectivBio (VECT), Fennec Pharmaceuticals (FRX), Redx Pharma (REDX) and Bioventix (BVXP). View all of FARN's competitors. What other stocks do shareholders of Faron Pharmaceuticals Oy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Faron Pharmaceuticals Oy investors own include Horizon Discovery Group plc (HZD.L) (HZD), (CELG), Acura Pharmaceuticals (ACUR), Carnival Co. & (CCL), Alphabet (GOOG), Hurricane Energy (HUR), International Consolidated Airlines Group (IAG), Northwest Pipe (NWPX), Petropavlovsk (POG) and TriQuint Semiconductor (TQNT). What is Faron Pharmaceuticals Oy's stock symbol? Faron Pharmaceuticals Oy trades on the London Stock Exchange (LON) under the ticker symbol "FARN." How do I buy shares of Faron Pharmaceuticals Oy? Shares of FARN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Faron Pharmaceuticals Oy's stock price today? One share of FARN stock can currently be purchased for approximately GBX 215. How much money does Faron Pharmaceuticals Oy make? Faron Pharmaceuticals Oy (LON:FARN) has a market capitalization of £114.45 million and generates £6.14 million in revenue each year. How many employees does Faron Pharmaceuticals Oy have? Faron Pharmaceuticals Oy employs 37 workers across the globe. How can I contact Faron Pharmaceuticals Oy? Faron Pharmaceuticals Oy's mailing address is Intelligate, Joukahaisenkatu 6, TURKU, 20520, Finland. The official website for Faron Pharmaceuticals Oy is www.faron.com. The company can be reached via phone at +358-2-4695151. This page (LON:FARN) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
